Write your message
Volume 4, Issue 3 (Summer 2019)                   J Obstet Gynecol Cancer Res 2019, 4(3): 117-119 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghaemi M, Shirali E, Yaradi F, Safavi M, Hemmatian O. Primary Vaginal Leiomyosarcoma: A Case Report and Review of the Articles. J Obstet Gynecol Cancer Res. 2019; 4 (3) :117-119
URL: http://jogcr.com/article-1-214-en.html
Gynecology & Obstetricia, Associated Professor, Kamali Hospital, Alborz University of Medical Sciences, Karaj, Iran , m_ghaemi@razi.tums.ac.ir
2- Associated Professor, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
3- Professor, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
4- Urologist, Uro-oncologist, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
5- MD, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (71 Views)

Background & Objective: Primary vaginal sarcomas are extremely rare and counts about 2-3% of all vaginal malignancies. We report a case with vaginal leiomyosarcoma which was treated by radical hysterectomy.
Case Report: A 46 year old woman from Iraq, referred to Yas Hospital by chief complaint of post-coital bleeding and a vaginal mass with pathology report of vaginal leiomyosarcoma. She underwent radical hysterectomy with bilateral salpingo-oophorectomy and partial vaginectomy (2/3 upper of the vagina). She refused to receive chemotherapy after surgery. In 3 years follow up, she did not have any recurrence.
Conclusion: Experiences about vaginal leiomyosarcoma are not sufficient due to rarity of the disease. However, based on review of the literature surgery is still the first choice followed by both chemotherapy and radiotherapy that are preferred based on current reports.

     

Experiences about vaginal leiomyosarcoma are not sufficient due to rarity of the disease. However, based on review of the literature surgery is still the first choice followed by both chemotherapy and radiotherapy that are preferred based on current reports.


Systematic Review: Case Report | Subject: Gynecology Oncology
Received: 2019/03/17 | Accepted: 2020/01/27 | Published: 2020/01/27

References
1. Keller NA, Godoy H. Leiomyosarcoma of the Vagina: An Exceedingly Rare Diagnosis. Case Rep Obstet Gynecol. 2015;2015:363895. [DOI:10.1155/2015/363895] [PMID] [PMCID] [DOI:10.1155/2015/363895] [PMID] [PMCID]
2. Jonathan S. Berek NFH. Berek & Hacker's Gynecologic Oncology. 6th edition ed: Wolters Kluwer; 2015.
3. Ben Amara F, Jaouadi M, Jouini H, Nasr M, Malek M, Neji K, et al. Primary leiomyosarcoma of the vagina. Case report and literature review. Tunis Med. 2007;85(1):68-70.
4. Khosla D, Patel FD, Kumar R, Gowda KK, Nijhawan R, Sharma SC. Leiomyosarcoma of the vagina: A rare entity with comprehensive review of the literature. Int J Appl Basic Med Res. 2014;4(2):128-30. [DOI:10.4103/2229-516X.136806] [PMID] [PMCID] [DOI:10.4103/2229-516X.136806] [PMID] [PMCID]
5. Tavassoli FA, Norris HJ. Smooth muscle tumors of the vagina. Obstet Gynecol. 1979;53(6):689-93.
6. Li L, Zhang R, Wu LY, Bai P, Li SM, Li HJ, et al. [Primary leiomyosarcoma of the vagina: a clinical analysis of 9 cases]. Zhonghua Fu Chan Ke Za Zhi. 2012;47(10):747-50.
7. Kurman RJ, Hedrick Ellenson, Lora, Ronnett, Brigitte M. Blaustein's Pathology of the Female Genital Tract: Springer; 2011. [DOI:10.1007/978-1-4419-0489-8] [DOI:10.1007/978-1-4419-0489-8]
8. Ciaravino G, Kapp DS, Vela AM, Fulton RS, Lum BL, Teng NN, et al. Primary leiomyosarcoma of the vagina. A case report and literature review. Int J Gynecol Cancer. 2000;10(4):340-7. [DOI:10.1046/j.1525-1438.2000.010004340.x] [PMID] [DOI:10.1046/j.1525-1438.2000.010004340.x] [PMID]
9. Peters WA, 3rd, Kumar NB, Andersen WA, Morley GW. Primary sarcoma of the adult vagina: a clinicopathologic study. Obstet Gynecol. 1985;65(5):699-704.
10. Curtin JP, Saigo P, Slucher B, Venkatraman ES, Mychalczak B, Hoskins WJ. Soft-tissue sarcoma of the vagina and vulva: a clinicopathologic study. Obstet Gynecol. 1995;86(2):269-72. [DOI:10.1016/0029-7844(95)00160-S] [DOI:10.1016/0029-7844(95)00160-S]
11. Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808-18. [DOI:10.1016/j.ejca.2008.01.019] [PMID] [DOI:10.1016/j.ejca.2008.01.019] [PMID]
12. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-81. [DOI:10.1002/cncr.23592] [PMID] [DOI:10.1002/cncr.23592] [PMID]
13. Hensley ML. Uterine/female genital sarcomas. Curr Treat Options Oncol. 2000;1(2):161-8. [DOI:10.1007/s11864-000-0061-6] [PMID] [DOI:10.1007/s11864-000-0061-6] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.